![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RPL31 |
Gene summary for RPL31 |
![]() |
Gene information | Species | Human | Gene symbol | RPL31 | Gene ID | 6160 |
Gene name | ribosomal protein L31 | |
Gene Alias | L31 | |
Cytomap | 2q11.2 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P62899 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6160 | RPL31 | P80T-E | Human | Esophagus | ESCC | 3.97e-70 | 3.26e+00 | 0.155 |
6160 | RPL31 | P82T-E | Human | Esophagus | ESCC | 1.03e-36 | 2.21e+00 | 0.1072 |
6160 | RPL31 | P83T-E | Human | Esophagus | ESCC | 2.06e-91 | 3.10e+00 | 0.1738 |
6160 | RPL31 | P84T-E | Human | Esophagus | ESCC | 3.46e-13 | 1.23e+00 | 0.0933 |
6160 | RPL31 | P89T-E | Human | Esophagus | ESCC | 2.52e-63 | 3.70e+00 | 0.1752 |
6160 | RPL31 | P91T-E | Human | Esophagus | ESCC | 7.47e-39 | 3.23e+00 | 0.1828 |
6160 | RPL31 | P94T-E | Human | Esophagus | ESCC | 1.79e-13 | 1.86e+00 | 0.0879 |
6160 | RPL31 | P104T-E | Human | Esophagus | ESCC | 3.57e-06 | 1.76e+00 | 0.0931 |
6160 | RPL31 | P107T-E | Human | Esophagus | ESCC | 2.81e-80 | 3.79e+00 | 0.171 |
6160 | RPL31 | P126T-E | Human | Esophagus | ESCC | 1.28e-22 | 2.07e+00 | 0.1125 |
6160 | RPL31 | P128T-E | Human | Esophagus | ESCC | 1.42e-78 | 3.01e+00 | 0.1241 |
6160 | RPL31 | P130T-E | Human | Esophagus | ESCC | 6.53e-84 | 2.98e+00 | 0.1676 |
6160 | RPL31 | NAFLD1 | Human | Liver | NAFLD | 8.78e-18 | -1.45e+00 | -0.04 |
6160 | RPL31 | S41 | Human | Liver | Cirrhotic | 1.45e-22 | -1.53e+00 | -0.0343 |
6160 | RPL31 | S42 | Human | Liver | HCC | 4.95e-02 | -8.90e-01 | -0.0103 |
6160 | RPL31 | S43 | Human | Liver | Cirrhotic | 1.61e-47 | -1.46e+00 | -0.0187 |
6160 | RPL31 | HCC1_Meng | Human | Liver | HCC | 3.88e-132 | -3.19e-01 | 0.0246 |
6160 | RPL31 | HCC2_Meng | Human | Liver | HCC | 3.69e-127 | -5.15e-01 | 0.0107 |
6160 | RPL31 | cirrhotic1 | Human | Liver | Cirrhotic | 2.39e-39 | 5.03e-01 | 0.0202 |
6160 | RPL31 | cirrhotic2 | Human | Liver | Cirrhotic | 6.29e-32 | 4.40e-01 | 0.0201 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
GO:00021814 | Colorectum | FAP | cytoplasmic translation | 76/2622 | 148/18723 | 3.31e-27 | 2.03e-23 | 76 |
GO:00021815 | Colorectum | CRC | cytoplasmic translation | 70/2078 | 148/18723 | 1.53e-28 | 9.16e-25 | 70 |
GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
GO:000218132 | Liver | Cyst | cytoplasmic translation | 70/496 | 148/18723 | 9.01e-71 | 3.85e-67 | 70 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL31 | SNV | Missense_Mutation | c.254N>A | p.Arg85His | p.R85H | P62899 | protein_coding | tolerated(0.42) | benign(0.021) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
RPL31 | SNV | Missense_Mutation | c.30N>T | p.Lys10Asn | p.K10N | P62899 | protein_coding | deleterious(0.03) | benign(0.176) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL31 | SNV | Missense_Mutation | c.167A>G | p.Glu56Gly | p.E56G | P62899 | protein_coding | deleterious(0.05) | benign(0.104) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
RPL31 | SNV | Missense_Mutation | c.281N>T | p.Glu94Val | p.E94V | P62899 | protein_coding | deleterious(0.03) | possibly_damaging(0.619) | TCGA-AA-3870-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR | |
RPL31 | SNV | Missense_Mutation | novel | c.329N>A | p.Pro110His | p.P110H | P62899 | protein_coding | deleterious(0.02) | possibly_damaging(0.625) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPL31 | SNV | Missense_Mutation | novel | c.47N>T | p.Ala16Val | p.A16V | P62899 | protein_coding | tolerated(0.06) | benign(0.157) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
RPL31 | SNV | Missense_Mutation | novel | c.74A>G | p.Tyr25Cys | p.Y25C | P62899 | protein_coding | tolerated(0.06) | benign(0.182) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RPL31 | SNV | Missense_Mutation | rs1065720 | c.284N>G | p.Asp95Gly | p.D95G | P62899 | protein_coding | deleterious(0.01) | benign(0.25) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL31 | SNV | Missense_Mutation | novel | c.31N>G | p.Lys11Glu | p.K11E | P62899 | protein_coding | deleterious(0.05) | benign(0.188) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL31 | SNV | Missense_Mutation | novel | c.154N>G | p.Phe52Val | p.F52V | P62899 | protein_coding | deleterious(0.02) | possibly_damaging(0.566) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |